Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026063 · ClinicalTrials.gov registry record · Phase 3
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
A Phase 3 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT02026063 is a Phase 3 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 124 participants.
The verdict
NCT02026063, a Phase 3 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Interventions
- DRUG Telotristat etiprate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2014-01-14 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026063
The ClinicalTrials.gov registry entry for NCT02026063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telotristat etiprate is the first listed.
NCT02026063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026063 about?
NCT02026063 is a clinical study titled "Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms". The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
What is the current status of trial NCT02026063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2014-01-14. Estimated completion is 2018-09-12.
What interventions are being tested in trial NCT02026063?
The interventions under investigation include: Telotristat etiprate (DRUG).
Who is sponsoring clinical trial NCT02026063?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.